European Union - English - EMA (European Medicines Agency)

eli lilly netherlands - pemetrexed - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.pemetrexed lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetine - neuralgia; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - duloxetine lilly is indicated in adults for:treatment of major depressive disordertreatment of diabetic peripheral neuropathic paintreatment of generalised anxiety disorderduloxetine lilly is indicated in adults.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - erectile dysfunction - urologicals - treatment of erectile dysfunction in adult males.in order for tadalafil to be effective, sexual stimulation is required.tadalafil lilly is not indicated for use by women.treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, non-small-cell lung - antineoplastic agents - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

eli lilly nederland b.v., netherlands - tadalafil - tablet - 5 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - idelalisib, quantity: 150 mg - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - zydelig in combination with rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll)/small lymphocytic lymphoma (sll) upon relapse in patients for whom chemo-immunotherapy is not considered suitable. ? zydelig in combination with ofatumumab is indicated for the treatment of adult patients with cll/sll upon relapse in patients for whom chemo-immunotherapy is not considered suitable. ? zydelig is indicated as monotherapy for the treatment of patients with follicular lymphoma which is refractory to at least two prior systemic therapies. the disease must be refractory to both rituximab and an alkylating agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - idelalisib, quantity: 100 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; hyprolose; magnesium stearate; croscarmellose sodium; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350 - ? zydelig in combination with rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll)/small lymphocytic lymphoma (sll) upon relapse in patients for whom chemo-immunotherapy is not considered suitable. ? zydelig in combination with ofatumumab is indicated for the treatment of adult patients with cll/sll upon relapse in patients for whom chemo-immunotherapy is not considered suitable. ? zydelig is indicated as monotherapy for the treatment of patients with follicular lymphoma which is refractory to at least two prior systemic therapies. the disease must be refractory to both rituximab and an alkylating agent.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - hypertension, pulmonary - urologicals - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5.1).efficacy has been shown in idiopathic pah (ipah) and in pah related to collagen vascular disease.paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetine - diabetic neuropathies - psychoanaleptics, - treatment of diabetic peripheral neuropathic pain.ariclaim is indicated in adults.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - drotrecogin alfa (activated) - sepsis; multiple organ failure - antithrombotic agents - xigris is indicated for the treatment of adult patients with severe sepsis with multiple organ failure when added to best standard care. the use of xigris should be considered mainly in situations when therapy can be started within 24 hours after the onset of organ failure (for further information see section 5.1).